跳至主要内容
临床试验/JPRN-UMIN000038683
JPRN-UMIN000038683招募中未知

Real-world observational study on the efficacy and safety of first-line osimertinib treatment and on post-progression patterns of care in patients with epidermal growth factor receptor activating mutation positive (EGFRm +) advanced non-small-cell lung cancer (NSCLC) -Reiwa- - CSPOR-LC07

Public Health Research Foundation, Comprehensive Support Project for Oncology Research (CSPOR)0 个研究点目标入组 700 人开始时间: 2019年11月26日最近更新:

试验速览

阶段
未知
状态
招募中
发起方
入组人数
700

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • (1)atients whose treatment date for EGFR TKIs was prior to September 1, 2018. Patients judged by the physician to be inappropriate for enrollment in the study. (2)Patients judged by the physician to be inappropriate for enrollment in the study.

研究者

发起方
Public Health Research Foundation, Comprehensive Support Project for Oncology Research (CSPOR)

相似试验